Soticlestat is a Small Molecule owned by Ovid Therapeutics, and is involved in 20 clinical trials, of which 14 were completed, 5 are ongoing, and 1 is planned.

Soticlestat inhibits cholesterol 24-hydroxylase. Inhibiting intracerebral cholesterol 24-hydroxylase leads to suppression of nerve cell death, Alpha-beta increase, intracerebral inflammation and the like observed in neurodegenerative diseases. Decreasing intracerebral 24-HC (cholesterol 24-hydroxylase) causes not only an improvement of the symptom but also a suppression of the progression.

The revenue for Soticlestat is expected to reach a total of $1.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Soticlestat NPV Report.

Soticlestat is originated and owned by Ovid Therapeutics. Takeda Pharmaceutical is the other company associated in development or marketing of Soticlestat.

Soticlestat Overview

Soticlestat (TAK-935, OV-935) is under development for the treatment of developmental and epileptic encephalopathies (dEE), rare pediatric epilepsies such as Dravet syndrome, LennoxGastaut syndrome, tuberous sclerosis complex, 15q duplication syndrome and CDKL5 deficiency disorder. It is administered orally. The drug candidate act by targeting cholesterol 24-hydroxylase. It was also under development for chronic complex regional pain syndrome.

Takeda Pharmaceutical Overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,002,307 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Soticlestat

Report Segments
  • Innovator
Drug Name
  • Soticlestat
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.